Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet Invited commentary: Anticoagulation in COVID-19 – The Lancet   Commentary on Twitter NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE […]

The post RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes. appeared first on Links Medicus.